--Biopharmaceutical company CSL (other-otc: CMXHF.PK - news - people ) has increased its search for products in late stages of research, hoping to take advantage of opportunities arising due to tough economic times.
CSL has appointed a specialist team to look into buying opportunities as other companies are 'better priced and more available than they had been in the past,' says CSL chief scientific officer and director of research, Andrew Cuthbertson.
CSL stock has outperformed the benchmark index for over a quarter, making it one of this year's better stocks. Page 42.
THE AUSTRALIAN (www.theaustralian.news.com.au)
AVX Price at posting:
9.2¢ Sentiment: None Disclosure: Not Held
